TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1633070
Drug: Ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 200 mg twice daily
Study: 6428911
Drug: Ouabain 0.5
Normalized name: ouabain 0.5 mg/2 mL INJECTION AMPUL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ouabain 0.5 mg i.v.
Study: 45539
Drug: Nitroglycerin 0.8
Normalized name: nitroglycerin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin 0.8 mg sublingual
Study: 6428911
Drug: Ouabain 12
Normalized name: ouabain
DrugBank: Ouabain (DB01092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ouabain 12 mg sublingual
Study: 30532195
Drug: NMES on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: NMES on medial gastrocnemius muscle (NMES-MG)
Study: 27845159
Drug: Continuous use
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous use of non-menthol combustible cigarettes (CC arm)
Study: 21335358
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of MK-0249 (H3RIA)
Study: 21335358
Drug: Stable alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stable alcohol level (0.6 g L(‐1))
Study: 18057478
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose candy (vitamin A 1000 IU and 14 mg elemental iron) daily
Study: 18057478
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose candy for 3 days a week
Study: 18057478
Drug: Half dose
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half dose candy (vitamin A 500 IU and 7 mg elemental iron) daily
Study: 16327947
Drug: DHEP/heparin (Flector
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEP/heparin (Flector Tissugel Heparin)
Study: 9809958
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 2% dodecafluoropentane emulsion (EchoGen)
Study: 2535086
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural analgesia with bupivacaine 0.125% and sufentanil 0.83 micrograms.ml‐1
Study: 2535086
Drug: Intravenous peroperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous peroperative and on-demand intramuscular postoperative analgesia with nicomorphine 0.2 mg.kg‐1
Study: 31815649
Drug: Upadacitinib 15
Normalized name: upadacitinib 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib 15 mg daily
Study: 31815649
Drug: Upadacitinib 30
Normalized name: upadacitinib 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib 30 mg daily
Study: 31407810
Drug: Subcutaneous Nexvax2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Nexvax2 (900 µg)
Study: 31407810
Drug: Intravenous Nexvax2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Nexvax2 (900 µg)
Study: 21471773
Drug: Sildenafil (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (initial dose of 50 mg, adjustable to 25 or 100 mg)
Study: 16158312
Drug: Oral topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral topotecan (1.2 mg/m2) once a day for 10 days
Study: 16158312
Drug: Oral topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral topotecan (1.2 mg/m2) twice a day for 5 days
Study: 16158312
Drug: Twice a
Normalized name: Pataday Twice A Day Relief
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice a day dosing of topotecan
Study: 16158312
Drug: Once a
Normalized name: Once A Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day dosing of topotecan
Study: 9394980
Drug: Acidic hot-spring
Normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acidic hot-spring bathing (10-min bath at 42 degrees C, twice daily)
Study: 8071832
Drug: Ceftibuten (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftibuten (400 mg every 12 h for 8 days)
Study: 29288545
Drug: Lorcaserin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcaserin (10 mg twice a day)
Study: 25718355
Drug: 24-month dual-antiplatelet
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 24-month dual-antiplatelet therapy (DAPT) in ACS patients
Study: 25718355
Drug: 6-month dual-antiplatelet
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month dual-antiplatelet therapy (DAPT) in ACS patients
Study: 25718355
Drug: 24-month dual-antiplatelet
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 24-month dual-antiplatelet therapy (DAPT) in SCAD patients
Study: 25718355
Drug: 6-month dual-antiplatelet
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month dual-antiplatelet therapy (DAPT) in SCAD patients
Study: 22323747
Drug: varenicline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: varenicline (1 mg twice daily for 4 weeks after 4 weeks of titration)
Study: 15983534
Drug: Isoflavones (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavones (5 mg/kg body weight)
Study: 15983534
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (500 mg) plus isoflavones (5 mg/kg body weight)
Study: 12027856
Drug: Group LBH
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group LBH (2.5 ml lignocaine 2%, 2.5 ml bupivacaine 0.5%, 15 IU hyaluronidase/ml and 0.125 ml isotonic saline)
Study: 12027856
Drug: Group LB
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group LB (2.5 ml lignocaine 2%, 2.5 ml bupivacaine 0.5% and 0.125 ml isotonic saline)
Study: 12027856
Drug: Group LBpH
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group LBpH (2.5 ml lignocaine 2%, 2.5 ml bupivacaine 0.5% and 0.125 ml sodium bicarbonate 8.4%)
Study: 12027856
Drug: Group LBHpH
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group LBHpH (2.5 ml lignocaine 2%, 2.5 ml bupivacaine 0.5%, 15 IU hyaluronidase/ml and 0.125 ml sodium bicarbonate 8.4%)
Study: 1822997
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg ISD (isosorbide dinitrate)
Study: 111104
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of slow-release xantinol nicotinate (XN) twice daily for 12 weeks
Study: 19819667
Drug: Subcutaneous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous morphine with 150U of recombinant human hyaluronidase (rHuPH20)
Study: 19819667
Drug: Subcutaneous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous morphine without recombinant human hyaluronidase (rHuPH20)
Study: 15494907
Drug: Intravenous ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous ribavirin (33 mg/kg followed by 16 mg/kg every 6 h for 4 days and 8 mg/kg every 8 h for 3 days)
Study: 15494907
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered for 7 days or until negative Sin Nombre virus antibody test)
Study: 11069502
Drug: UVA sunbed
Normalized name: UVA URSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVA sunbed treatment
Study: 8443028
Drug: metoprolol-Oros 14/190
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol-Oros 14/190 once daily
Study: 8443028
Drug: propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: propranolol 80 mg twice daily
Study: 8443028
Drug: temazepam 10
Normalized name: temazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: temazepam 10 mg once daily
Study: 3533085
Drug: indoprofen 200
Normalized name: Neoprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: indoprofen 200 mg
Study: 27187447
Drug: Q‐Mix (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q‐Mix (1000 mg quercetin, 400 mg isoquercetin, 120 mg EGCG, 400 mg n3‐PUFAs, 1000 mg vitamin C, 40 mg niacinamide, 800 µg folic acid)
Study: 22554876
Drug: Early postoperative
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early postoperative physical therapy protocol (passive elevation and rotation starting at postoperative day 2)
Study: 22554876
Drug: Delayed postoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed postoperative physical therapy protocol (passive elevation and rotation starting at 6 weeks)
Study: 19468821
Drug: Urinary excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary excretion of amino acids
Study: 16549375
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg loading dose, followed by 75 mg daily for 30 days)
Study: 15298642
Drug: Rapid immunochromatographic
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid immunochromatographic stool test before treatment
Study: 15298642
Drug: Rapid immunochromatographic
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid immunochromatographic stool test after treatment
Study: 11380832
Drug: losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 50 mg q.d. added to lisinopril 40 mg q.d. and other antihypertensive therapy
Study: 11380832
Drug: lisinopril 40
Normalized name: lisinopril 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril 40 mg q.d. and other antihypertensive therapy
Study: 3433015
Drug: Pentagastrin infusion
Normalized name: pentagastrin
DrugBank: Pentagastrin (DB00183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentagastrin infusion (0.9 micrograms/kg/h, intravenously)
Study: 29732223
Drug: Mesh nebulizer
Normalized name: Aura Portaneb Mesh Nebulizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesh nebulizer with salbutamol inhalation solution (0.2 ml for children ≧ 2 years old)
Study: 29732223
Drug: Jet nebulizer
Normalized name: Pari LC Jet Nebulizer Plus RE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet nebulizer with salbutamol inhalation solution (0.2 ml for children ≧ 2 years old)
Study: 29732223
Drug: Mesh nebulizer
Normalized name: Aura Portaneb Mesh Nebulizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesh nebulizer with salbutamol inhalation solution (0.1 ml for children < 2 years old)
Study: 29732223
Drug: Jet nebulizer
Normalized name: Pari LC Jet Nebulizer Plus RE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet nebulizer with salbutamol inhalation solution (0.1 ml for children < 2 years old)
Study: 27757026
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 50 mg/d for 5-8 years
Study: 26482768
Drug: Androgen Deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen Deprivation Therapy (ADT)
Study: 19684008
Drug: AREDS medication
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AREDS medication
Study: 9282505
Drug: Sodium antimony
Normalized name: Sodium antimonyl gluconate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium antimony gluconate (SAG) at a dose of 20 mg/kg/day up to a maximum of 850 mg/day for 4 weeks
Study: 9282505
Drug: Ketoconazole at
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole at a dose of 600 mg/day in 3 divided doses for 4 weeks
Study: 8280551
Drug: i.v. ondansetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ondansetron 4 mg
Study: 23876566
Drug: Compassion‐Mindfulness Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compassion‐Mindfulness Therapy (C‐MT)
Study: 18662492
Drug: Duloxetine 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 120 mg QD
Study: 18662492
Drug: Duloxetine 60-120
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60-120 mg QD
Study: 12666950
Drug: Alendronate sodium
Normalized name: Alendronate Sodium
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate sodium (fosamax), one tablet every morning for six months
Study: 11421377
Drug: Atovaquone-proguanil (AP)
Normalized name: atovaquone / proguanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atovaquone-proguanil (AP) 1,000 mg + 400 mg once daily for 3 days
Study: 11421377
Drug: Halofantrine (HF)
DrugBank: Halofantrine (DB01218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Halofantrine (HF) 1,500 mg in 3 doses
Study: 8840413
Drug: Famciclovir 500
Normalized name: famciclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir 500 mg three times daily for 7 days
Study: 1643886
Drug: Almagate (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almagate (0.25 to 0.5 mL/kg every 2 hrs by nasogastric tube)
Study: 1643886
Drug: Ranitidine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (1.5 mg/kg every 6 hrs iv)
Study: 1643886
Drug: Sucralfate (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (0.5 to 1 g every 6 hrs by nasogastric tube)
Study: 6338251
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (estramustine phosphate plus cis-platinum)
Study: 28420122
Drug: High-salt diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-salt diet (18.0 g/day of NaCl)
Study: 28420122
Drug: High-salt diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-salt diet supplemented with potassium (18.0 g/day of NaCl + 4.5 g/day of KCl)
Study: 28420122
Drug: Low-salt diet
Normalized name: Low-energy diets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-salt diet (3.0 g/day of NaCl)
Study: 26054688
Drug: Prolonged capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prolonged capecitabine chemotherapy (1000mg/m² twice daily on days 1-14 of a 3-week cycle for eight cycles after eight cycles of XELOX)
Study: 26054688
Drug: XELOX (oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: XELOX (oxaliplatin 130mg/m² on day 1 and oral capecitabine 1000mg/m² twice daily on days 1-14 of a 3-week cycle for eight cycles)
Study: 23803900
Drug: 7.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 μg dose of whole-virion inactivated H5N1 vaccine
Study: 23803900
Drug: 15 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 μg dose of whole-virion inactivated H5N1 vaccine
Study: 11453910
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy with mTHPC (0.1 mg kg(‐1) intravenous injection) and light doses of 10 or 15 J cm(‐2) on days 1 or 2 after injection.
Study: 11453910
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy with mTHPC (0.1 mg kg(‐1) intravenous injection) and light doses of 5-15 J cm(‐2).
Study: 9236900
Drug: Post-operative brachytherapy
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative brachytherapy (BT) with a mean dose of 57 Gy (range: 50-60)
Study: 9236900
Drug: Post-operative external
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative external beam irradiation (EBI) with a mean dose of 50 Gy
Study: 8325311
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (streptokinase and anistreplase)
Study: 28333353
Drug: Atazanavir/ritonavir+lamivudine dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/ritonavir+lamivudine dual therapy
Study: 28333353
Drug: Atazanavir/ritonavir-based triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/ritonavir-based triple therapy
Study: 28333353
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between dual therapy and triple therapy
Study: 26345959
Drug: DC-CIK therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: DC-CIK therapy combined with docetaxel-cisplatin chemotherapy and synchronization conformal radiotherapy
Study: 26345959
Drug: Docetaxel-cisplatin chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel-cisplatin chemotherapy and synchronization conformal radiotherapy
Study: 20078006
Drug: Potential solutions
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potential solutions to research challenges
Study: 12470180
Drug: DZP rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: DZP rectal gel
Study: 1161345
Drug: Calcium lactate,
Normalized name: Calcium Lactate, 325 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium lactate, 800 mg/kg/24 hr in divided doses with each feed (group B)
Study: 1161345
Drug: No calcium
Normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No calcium supplement (group A)
Study: 31689708
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (160 U)
Study: 24248687
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Lapatinib and Trastuzumab (Arm C)
Study: 19357536
Drug: Annual low
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual low dose CT scans for 5 years
Study: 15480130
Drug: Manipulative Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manipulative Therapy (MT)
Study: 29068153
Drug: ciNPT (PREVENA™
Approvals — FDA: no, EMA: no, PMDA: no
Description: ciNPT (PREVENA™ Therapy)
Study: 24535360
Drug: Propofol TCI
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol TCI + 0.8 μg/kg fentanyl
Study: 24535360
Drug: Propofol TCI
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol TCI + 40 mg lidocaine
Study: 17072055
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids for 2 months
Study: 10831691
Drug: Gadobenate dimeglumine
Normalized name: Gadobenate Dimeglumine
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadobenate dimeglumine (Gd‐BOPTA) 0.05‐mmol/kg dose administered before and after imaging
Study: 10831691
Drug: Gadobenate dimeglumine
Normalized name: Gadobenate Dimeglumine
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadobenate dimeglumine (Gd‐BOPTA) 0.1‐mmol/kg dose administered before and after imaging
Study: 8800891
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics perioperatively (Group I)
Study: 27220574
Drug: Antiarrhythmics drugs
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmics drugs cardioversion
Study: 20148906
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 mg/day) and Diet alone
Study: 18597226
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard propofol titration)
Study: 12018972
Drug: Sorbitol (1305
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbitol (1305 mg)
Study: 10622070
Drug: Clarithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (500 mg) every 12 hours for 5-10 days
Study: 7575745
Drug: New sotalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: New sotalol hydrochloride tablet (160 mg)
Study: 30026514
Drug: Jerusalem artichoke
Normalized name: JERUSALEM ARTICHOKE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jerusalem artichoke and fermented soybean powder mixture (40g daily for 12 weeks)
Study: 27528117
Drug: Androgen suppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen suppression (secondary treatment)
Study: 26875300
Drug: Low-dose ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose ferric EDTA (2.5 mg of iron)
Study: 26875300
Drug: High-dose ferrous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ferrous lactate (10 mg of iron)
Study: 18697192
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid solution inducing hyperammonemia
Study: 18697192
Drug: p38(MAPK) agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: p38(MAPK) agonist
Study: 15813840
Drug: ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 8 mg intravenous bolus followed by oral ondansetron 8 mg twice daily for 5 days
Study: 12560224
Drug: Randomized selection
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized selection trials evaluating several therapies based on multiple outcomes
Study: 8478660
Drug: Doxorubicin-containing therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin-containing therapy (CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone)
Study: 8478660
Drug: Doxorubicin-containing therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin-containing therapy (CHOP)
Study: 3092659
Drug: cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: cimetidine (400 mg twice daily)
Study: 30379624
Drug: Documented cardiotoxicity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Documented cardiotoxicity during on-protocol therapy
Study: 20515600
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A plus upper limb therapy programme
Study: 20515600
Drug: Upper limb
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upper limb therapy programme alone
Study: 23342679
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A plus therapy
Study: 16703311
Drug: iomeprol 300
Normalized name: Iomeprol 300 MG/1 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: iomeprol 300 (iodine concentration: 300 mg/ml)
Study: 16703311
Drug: iomeprol 400
Normalized name: Iomeprol 400 MG/1 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: iomeprol 400 (iodine concentration: 400 mg/ml)